Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Kalamazoo Valley Adds Medical Cannabis Courses to Its Cannabis Education Program


“There is so much confusion about what medical cannabis is and how to use it,” said Medical Cannabis Mentor Founder and CEO Joe Dolce.

Expanding on its popular workforce cannabis training program, Kalamazoo Valley Community College today announced that it will offer an online medical cannabis education course.

Through a unique partnership with Medical Cannabis Mentor, a leader in online medical cannabis education, Kalamazoo Valley will offer Cannabis Therapeutics 2022, an in-depth, foundational self-paced course for healthcare providers, dispensary personnel and patients. Kalamazoo Valley is Medical Cannabis Mentor’s first community college partner.

“Through conversations with community members and patients, we learned there was a lack of formal and easily accessible education for understanding the various therapeutic components of cannabis,” said Craig Jbara, vice president for strategic and business development at Kalamazoo Valley. “We believe it is important to promote accurate information and, if appropriate, provide an opportunity for improved quality of life in our community.”

The college will begin offering the self-paced, online training starting today, Oct. 24. The certificate program costs $299 and should take between eight to 10 hours to complete.

“There is so much confusion about what medical cannabis is and how to use it,” said Medical Cannabis Mentor Founder and CEO Joe Dolce. “That’s why our mission is ‘Education Before Medication.’ The goal is to separate myth from fact and to bring professionals and patients up to speed quickly. Our materials are based on the latest research and data from the world’s leading scientists and clinicians.”

After the successful completion of the virtual training units, participants will earn a certificate of completion from Kalamazoo Valley Community College and Medical Cannabis Mentors.

Medical Cannabis Mentor online programs are evidence-based and have been vetted and approved by healthcare professions and health agencies, such as New York’s Department of Health.

For more information, visit http://www.kvcc.edu/cannabis.

Share article on social media or email:

Echosens and ChronWell Announce Exclusive Strategic Partnership Between FibroScan and LIVErHEALTHY to Improve Patient Outcomes and Cost Savings


News Image

“NAFLD and NASH remain a silent and dangerous epidemic for over 80 million Americans. We are proud to partner with Echosens to offer healthcare providers and payers a scalable and cost-effective way to identify and treat those suffering from this alarming condition.” Joe Rubinsztain, CEO, ChronWell.

Echosens North America, a high-technology company offering the FibroScan® portfolio of solutions, and ChronWell, a digital health and therapeutics company targeting metabolic conditions like non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), today announce an exclusive strategic partnership to offer LIVErHEALTHY™ in conjunction with FibroScan. Under this exclusive agreement, Echosens and ChronWell will expand digital collaboration between their platforms and co-promote FibroScan and LIVErHEALTHY, respectively, as the preferred non-invasive testing and digital therapeutic platform for NAFLD and NASH.

“NAFLD and NASH remain a silent and dangerous epidemic for over 80 million Americans,” says Joe Rubinsztain, CEO, ChronWell. “We are proud to partner with Echosens to offer healthcare providers and payers a scalable and cost-effective way to identify and treat those suffering from this alarming condition.”

NAFLD, a common metabolic liver disease caused by fat accumulation in the liver, and its more severe form NASH, are ‘silent’ diseases and asymptomatic in their early stages. As a result, many go undiagnosed. Between 5-12% of people with NASH will progress to cirrhosis, late-stage scarring in the liver. Liver damage from cirrhosis generally can’t be reversed unless diagnosed and treated earlier in the disease progression.

“This strategic partnership is a powerful combination that reflects our collective commitment to ending the epidemic of fatty liver disease and halting the progression of NAFLD/NASH,” says Jon Gingrich, CEO of Echosens North America. “LIVErHEALTHY complements our FibroScan platform, which includes solutions for hospitals, clinics, and private practices. Together, these important tools will support liver programs to ultimately improve patient outcomes.”

The risk of progression to advanced liver disease, including liver cancer, is higher in people with NASH than in the general population, and NASH is predicted to be the leading cause of liver transplantation by 2030. Moreover, NASH increases the risk of developing cardiovascular disease. Currently, no treatment is globally approved for the treatment of NASH, and patients with NASH are left with very few management options.

“Early assessment, detection and monitoring of liver disease hold the key to preventing this disease,” Gingrich continues. “Working collaboratively with our partners, we can demonstrate to payers, employers and other entities at risk for the cost of healthcare, that LIVErHEALTHY plus FibroScan is a cost-effective approach to diagnosing and treating NAFLD/NASH. With shared dedication and alignment to value-based care, we look forward to supporting the marketplace as it prepares for the entry of specialty pharmaceuticals.”

About Echosens

Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 3,500 peer-reviewed publications and 160 international guidelines. Examinations are covered by Medicare, Medicaid and many insurance plans. For more information, please visit https://www.echosens.com/.

About ChronWell

ChronWell is a digital health and therapeutics company targeting metabolic conditions like NAFLD and NASH through LIVErHEALTHY™, its digital health platform. ChronWell offers healthcare providers and payors a highly automated, scalable and profitable solution to detect and manage NAFLD using clinical best-practices in partnership with the leading diagnostic and therapeutic leaders in the field. For more information, follow us on LinkedIn or visit chronwell.com.

Share article on social media or email:

Michael Wilkerson releases new book Why America Matters


News Image

Why America Matters confronts the most challenging questions facing our nation today and points the way towards an American renaissance.

While exploring the meaning of American exceptionalism in a postmodern, post-exceptional world, Wilkerson unpacks the cultural phenomena that have defined our generation, all within the historical context and framework of the unique American experiment: the foundational ideas of life, liberty, and the pursuit of happiness. Wilkerson’s first book, Stormwall, anticipated looming inflation and identified the crisis in American democracy leading up to the 2020 election. Why America Matters picks up where Stormwall left off, revealing not just the multiple crises facing the nation, but importantly prescribing real solutions relevant for all Americans.

“I wrote this book to remind us of forgotten truths about America’s meaning, and about our country’s role in the world,” said Wilkerson. “I want to breathe hope and life into this great nation’s future, which can only be done by understanding our past—with its successes and failures. Why America Matters confirms that it’s not too late to find a way forward amidst a growing struggle for the soul and future of the only place we Americans have to call home.”

Wilkerson has written for The American Conservative, American Greatness, The American Spectator, Barron’s, The Epoch Times, The Hill, Jackson Hole Economics, and Marketwatch, among others. He was the Chief Executive Officer of Fairfax Africa Holdings Corporation, a leading emerging markets investment firm, and previously served as Managing Director at Lazard, one of the world’s preeminent financial advisory and asset management firms. Wilkerson is chairman of charity: water, a nonprofit organization bringing clean and safe water to people around the world. He holds an MBA from Harvard Business School, an MA in International Relations from Yale University, and a BS from Oral Roberts University.

Please visit http://www.whyamericamatters.com for more information on the book, and http://www.stormwall.com for more information on Wilkerson, his writings, and his passions.

Share article on social media or email:

MEDIA ALERT — Addressing the Opioid Crisis; Baltimore to Host AATOD 2022, Global Gathering of Policy Makers, Experts


When: Sunday, October 30 through Thursday, November 3, 2022

Where: Baltimore Hilton Inner Harbor, 401 W. Pratt Street, Baltimore, MD 21201 What: American Association for the Treatment of Opioid Dependence (AATOD) 2022 Conference: “The Power of Collaboration”

Co-hosted by: Opioid Treatment Providers of Maryland and the Maryland Department of Health — Behavioral Health Administration.


  • Speakers include the Director of the White House Office of National Drug Control Policy Dr. Rahul Gupta and HHS Assistant Secretary for Mental Health and Substance Use and the Leader of SAMHSA Miriam Delphin-Rittmon, Ph.D.

Why: The U.S. recently passed the benchmark of 100,000 deaths over a 12-month period from accidental drug overdose (OD). COVID-19 brought about several temporary changes to the way medication-assisted treatment (MAT) for opioid use disorder (OUD), including methadone administration, is provided to patients through our nation’s opioid treatment programs (OTPs). Currently, there is widespread discussion and controversy about what changes should be made permanent and what other changes should be considered.

VIP Speaker Highlights — Open to News Media:

  • Tuesday, November 1: 8:45 AM – 10:15 AM – Opening Plenary. Robin E. Rickard, JD, Executive Director, Opioid Operational Command Center, Crownsville, MD; Mark W. Parrino, M.P.A., President, AATOD; Rahul Gupta, MD, MPH, MBA, FACP, Director of the White House Office of National Drug Control Policy (ONDCP). Moderated by Kenneth B. Stoller, MD, DLFAPA, Director, Johns Hopkins Broadway Center for Addiction; Associate Professor, Department of Psychiatry, Johns Hopkins University School of Medicine.
  • Wednesday, November 2: 9:15 AM – 10:45 AM – Middle Plenary. Kathleen Rebbert-Franklin, LCSW-C, Director, Service Access and Practice Innovation, Maryland Department of Health, Behavioral Health Administration, Catonsville, MD(advanced scheduling requested); Babak Imanoel, DO, Medical Director, Northern Parkway Treatment Services, Baltimore, MD; Gregory Branch, MD, MBA, CPE, Health Officer, and Director, Baltimore, MD. Moderated by Vickie Walters, LCSW-C, Executive Director, Institutes for Behavior Resources, Inc, Baltimore, MD.
  • Thursday, November 3: 11:45 AM – 1:00 PM – Closing Plenary. Miriam E. Delphin-Rittmon, Ph.D., the HHS Assistant Secretary for Mental Health and Substance Use and the leader of the Substance Abuse and Mental Health Services Administration (SAMHSA). Moderated by Mark Parrino/AATOD.

Call in advance to secure onsite interviews; same-day requests honored as possible. Media are encouraged to cover all workshops, hot topic roundtables, and plenary sessions but will not be attending preconference sessions, invitation-only events, or any meetings specifically closed to the public. Press encouraged to pre-register. #aatod2022

Share article on social media or email:

New Book, “The Simple Guide to a Successful You,” Reveals How a Human Trafficking Survivor Took Control of Her Life and Found Her Dream Career


Sarah Lebel

Sarah Lebel

Especially in light of more people acknowledging their trauma with initiatives like the Me Too movement, I believe that there is a gap in resources for people like me, and the millions of other survivors, that are wondering ‘what’s next?’ in their life journey.

With her first book, “The Simple Guide to a Successful You: Navigating Your Career After Life Gets Messy,” author Sarah Lebel delivers her own heart wrenching true story of surviving human trafficking and the steps she took to get control of her life and ultimately find her dream career.

“The Simple Guide to a Successful You” pragmatically shares a variety of her own experiences as a human trafficking survivor navigating the workplace, and the tactics she used to begin discovering her passions and climbing the career ladder. Hope and optimism are prevalent, but it does not ignore the harsh reality that life can get messy for anyone.

“As a survivor of human trafficking that is now living a life that I never dreamed I could have, I feel it is my duty to share my own experience with other people. Especially in light of more people acknowledging their trauma with initiatives like the Me Too movement, I believe that there is a gap in resources for people like me, and the millions of other survivors, that are wondering ‘what’s next?’ in their life journey,” Lebel says. “Trauma can happen to anyone. My hope is that this book shines a light on the fact that no matter what has happened in your life, there is hope.”

“Each of the steps that I outlined in this book are based on my own experience, and even if just one reader is able to carve a passion-filled life path, that’s all that matters,” Lebel said. “If it motivates someone to take action and as a result a life is renewed, or a family is healed, then mission accomplished.”

“The Simple Guide to a Successful You” is now available in ebook and print versions at Amazon.

About the Author

Sarah Lebel is a survivor and advocate in the fight against human trafficking. As a result of her personal experiences, she founded the non-profit But What Is Next, which supports trauma survivors in creating a fulfilling and stable life by connecting them with resources to carve out their career path, and the financial support to make it happen.

Share article on social media or email:

Using Single-Cell DNA Sequencing to Unravel Clonal Heterogeneity & Progression to Richter’s Transformation in CLL, Upcoming Webinar Hosted by Xtalks


The speaker will discuss how single-cell DNA sequencing allowed high-sensitivity detection of driver mutations that bulk next-generation sequencing didn’t call, identifying minute subclones at the time of CLL diagnosis which were dormant for six to 19 years until rapid expansion at transformation.

Richter’s transformation (RT) is a rare condition in patients with chronic lymphocytic leukemia (CLL) which transforms into a much more aggressive form of B cell lymphoma, conferring a poor prognosis. The mechanisms and molecular changes that drive RT remain largely unknown. In this webinar, the featured speaker, Dr. Ferran Nadeu, will discuss their research study recently published in Nature Medicine where they applied single-cell DNA sequencing (scDNA-seq) to resolve clonal heterogeneity and detect rare pre-existing mutations associated with disease transformation.

To identify the genetic driver mutations and evolutionary histories over the disease course, Dr. Nadeu’s lab first sequenced the whole genome of 54 longitudinal samples covering up to 19 years of disease course in 19 cases of CLL developing RT. They then performed single-cell DNA sequencing using the Tapestri Platform and the 32-gene CLL Catalog Panel from Mission Bio on 16 longitudinal samples of four cases to validate these evolutionary histories of RT, and to track early driver mutations over the disease course.

The speaker will discuss how single-cell DNA sequencing allowed high-sensitivity detection of driver mutations that bulk next-generation sequencing didn’t call, identifying minute subclones at the time of CLL diagnosis which were dormant for six to 19 years until rapid expansion at transformation. He will also overview the findings from the study that suggest that CLL evolution to RT is driven by pre-existing subclones generated before diagnosis and that early intervention to eradicate the dormant RT subclones may prevent the future development of this lethal complication of CLL, uncovering potential therapeutic targets for RT.

Register to learn about unraveling clonal heterogeneity & progression to Richter’s transformation in chronic lymphocytic leukemia with single-cell DNA sequencing.

Join Ferran Nadeu, Postdoctoral Researcher, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, for the live webinar on Monday, November 7, 2022, at 10am EST (4pm CET/EU-Central).

For more information, or to register for this event, visit Using Single-Cell DNA Sequencing to Unravel Clonal Heterogeneity & Progression to Richter’s Transformation in CLL.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

How can Humanized Mouse Models be Used to Study Cancer & the Development of New Immune-Targeted Therapies? Upcoming Webinar Hosted by Xtalks


The webinar will explore how humanized mouse models allow the assessment of immune-checkpoint inhibitors, cell therapies, vaccines or antibodies and other drugs.

In this webinar, the featured speakers will describe humanized immune system mouse models and how they can support preclinical drug development. The webinar will explore how humanized mouse models allow the assessment of immune-checkpoint inhibitors, cell therapies, vaccines or antibodies and other drugs.

First, speaker Sebastien Tabruyn will talk about the advantages of the humanized mouse models with human immune system (HIS) for immunology and oncology research and preclinical study techniques.

Next, speaker Wout de Wispelaere will present an application of humanized mice in the study of aggressive tumors: uterine leiomyosarcomas (uLMS) and a pathway to initiate an anti-tumor adaptive immune response.

Register to learn how humanized mouse models can be used to study cancer and the development of new immune-targeted therapies.

Join Wout de Wispelaere, PhD Researcher, University of KU Leuven; and Sebastien Tabruyn, PhD, Chief Scientific Officer, General Manager, TransCure bioServices, for the live webinar on Tuesday, November 8, 2022, 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit How can Humanized Mouse Models be Used to Study Cancer & the Development of New Immune-Targeted Therapies?

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

HMP Global’s 2022 Cocaine, Meth & Stimulant Summit addresses surge in stimulant misuse, illicit drug use and addiction


Stimulant Summit logo

The Cocaine, Meth & Stimulant Summit will offer front-line professionals fighting this crisis the strategies and best practices needed to address stimulant misuse in their communities.

America’s addiction and overdose epidemic is reaching record levels, with stimulants becoming increasingly prevalent throughout the country.

Organized by HMP Global, the omnichannel leader in healthcare events and education, the 2022 Cocaine, Meth & Stimulant Summit will offer front-line healthcare and law enforcement professionals fighting this crisis the strategies and best practices needed to address stimulant misuse in their communities.

The Summit will be held virtually November 2-4, providing top quality training and education for clinical, law enforcement, and public health professionals. Now in its fifth year, the 2022 agenda features leading experts at the national, state, and local levels working to address the surge in illicit drug use and addiction in the United States.

“The opioid epidemic made headlines while the stimulant crisis loomed closely behind,” said Doug Edwards, Senior Vice President at HMP Global and Director of the Psychiatry & Behavioral Health Learning Network. “It is estimated that 5 million Americans misuse prescription stimulants, and more than 2 million American teens and adults reported past-year methamphetamine use. Compounding this issue, counterfeit prescription pills are being laced with illicit drugs in alarming amounts. It is urgent that we work together to find solutions. We cannot afford to lose more ground, for more lives to be lost.”

The Summit opening session features a documentary style video about the border community of Yuma, Ariz., “Perspectives on the Stimulant Crisis and the Impact on One Community.” Considerable amounts of fentanyl and other illicit substances come into the U.S. through its southern border. This documentary shows the devastating impact for families, schools, and communities, and how stakeholders throughout Yuma County are working together and making progress in addressing this crisis.

Other key presentations include:


  • The National Stimulant Use Landscape: Reviewing Data and Trends
  • Stimulant Use Disorder Response and Treatments — Insight from the National Institute on Drug Abuse
  • At the Intersection of Methamphetamine and Fentanyl: Trends in Use Patterns, Morbidity and Mortality in the U.S. Stimulant/Opioid Epidemic
  • Federal Government Voices — Policy Updates
  • Addressing Methamphetamine as an Emerging Threat: Overview of Federal Response Plan
  • Customizing Stimulant Use Responses Based on Community Unique Needs and Location
  • Takeaway Messages on the Stimulant Crisis from State Government Officials

Led by multi-disciplinary experts from across the nation, the Summit provides an extensive educational experience for professionals on the front lines of this rising epidemic. Featured speakers include:

  • Rahul Gupta, MD, Director, Office of National Drug Control Policy
  • Robert Califf, MD, Commissioner, Food and Drugs Administration
  • Nora Volkow, MD, Director, National Institute on Drug Abuse
  • Debra Houry, MD, Acting Principal Deputy Director, Centers for Disease Control and Prevention; Director, National Center for Injury Prevention and Control
  • Jennifer Smith, Secretary, Pennsylvania Department of Drug and Alcohol Programs
  • John Eadie, MPA, Coordinator, Public Health and Prescription Drug Monitoring Program Project, National Emerging Threats Initiative, A National HIDTA Initiative
  • Daniel Ciccarone, MD, Professor of Family and Community Medicine, University of California, San Francisco

The Cocaine, Meth & Stimulant Summit is designed and accredited for professionals in the fields of addiction, behavioral, and mental health, and law enforcement and public safety. It brings together law enforcement and treatment providers to discuss strategies to prevent stimulant misuse, provide access to treatment, and ensure that stimulants are part of larger social discussions about addressing drug use.

The Summit is a sister event to the Rx and Illicit Drug Summit, the largest national collaboration of professionals from local, state, and federal agencies, business, academia, treatment providers, and allied communities impacted by prescription drug misuse and heroin use. Rx Summit is the leading event for decision-makers and allied professionals working to address this public health emergency.

For more information, sponsorship opportunities, or to register for the Cocaine, Meth & Stimulant Summit, visit stimulantsummit.com.

ABOUT HMP GLOBAL 

HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

Share article on social media or email:

IntellectAbility and NPACE Partner to Bring Vital IDD Healthcare Education to Clinicians to Reduce Health Disparities for People With IDD


News Image

IntellectAbility’s Curriculum in IDD Healthcare teaches the fundamentals of IDD healthcare, providing StationMD clinicians with pertinent, practical information which is critical to the provision of IDD competent telehealth supports

According to the National Council on Disability Health Equity Framework for People with Disabilities,¹ people with IDD face significant, preventable health disparities. In a call to action to improve the healthcare provided to people with IDD, the framework recommends comprehensive disability clinical-care curricula be required for nursing and healthcare professionals. The goal is to empower healthcare professionals to better understand the healthcare needs of people with IDD. To respond to this need, IntellectAbility and NPACE are partnering to give healthcare providers practical and immediately usable clinical knowledge to improve healthcare for people with IDD, using the online Curriculum in IDD Healthcare (CIDDH).

People with IDD present unique health challenges that practicing physicians, nurse practitioners, physician assistants, nurses, and other healthcare professionals are often unprepared to address. Implementing the Curriculum in IDD Healthcare has shown to be effective in improving IDD clinical competency among healthcare providers and students. Feedback from clinicians and students who took the course shows that the CIDDH is doing precisely that.

“IntellectAbility’s Curriculum in IDD Healthcare teaches the fundamentals of IDD healthcare, providing StationMD clinicians with pertinent, practical information which is critical to the provision of IDD competent telehealth supports”, shares Dr. Maulik Trivedi, Chief Strategy Officer of StationMD. “That is why we at Station MD use the CIDDH to educate our physicians and nurse practitioners.”

IntellectAbility is partnering with NPACE to make the curriculum more widely available to Nurse Practitioners who encounter people with IDD on a regular basis and, as a result, need access to pertinent, practical information designed to enhance their IDD healthcare competence.

This online course is specifically created for clinicians, including physicians, nurse practitioners, physician assistants, dentists, nurses, allied health professionals, and students of these disciplines. It was written and delivered by Craig Escudé, MD, FAAFP, FAADM, with over 20 years of experience providing medical care for people with IDD and teaching others about this area of medicine on a national level.

“We are excited to partner with IntellectAbility to provide IDD healthcare-specific education and training to nurse practitioners and other clinicians. Through a dedicated curriculum in IDD healthcare, we believe we can work together to overcome health disparities,” states Josh Plotkin, COO at NPACE.

Eliminating barriers to health equity allows people with IDD to participate fully in all aspects of community life, realize their dreams, and mitigate the impacts of poor health and the burden of chronic disease. This mission has led these organizations to lead the way in improved training and educational opportunities for healthcare providers. To learn more, visit http://www.ReplacingRisk.com.

About IntellectAbility

IntellectAbility provides tools and training to agencies, governmental entities, and supporters of people with intellectual and developmental disabilities to foster early recognition and mitigation of health risks, thereby improving health and wellness. One such tool is the Health Risk Screening Tool (HRST), of which they are the sole developer, producer, and distributor. The web-based HRST is the most widely used and validated health risk screening instrument for people with intellectual and developmental disabilities. IntellectAbility also provides numerous health-related and person-centered service trainings for supporters of people with IDD. With unrelenting focus, IntellectAbility works to fulfill its mission of improving health and quality of life for people with intellectual and developmental disabilities and other at-risk populations. For more information, visit http://www.ReplacingRisk.com.

Reference:

1. “Health Equity Framework for People with Disabilities.” Released February 2022, Updated August 2022. National Council on Disability.https://ncd.gov/sites/default/files/NCD_Health_Equity_Framework.pdf

Share article on social media or email:

Hospitals Seek High-Tech Solutions to Meet Telehealth Demands


News Image

Portable telemetry for on-site use and remote telemetry for home use are the logical next steps in this era of virtual care. Telehealth is only growing in popularity and effectiveness. Now is the time for hospitals to augment their current telehealth practices with robust yet adaptable technology.

In 2020, the COVID-19 pandemic dramatically changed hospital operations. As facilities limited non-COVID care, medical providers turned to telehealth solutions to treat patients.(1) Patients and providers relied on a patchwork of videoconferencing systems, patient portals, and rudimentary home health equipment to manage non-emergency care. “Value-based care means flexibility in clinical capability,” says The Virtual Telemetry Company, InfoBionic, CEO Stuart Long. “Portable telemetry for on-site use and remote telemetry for home use are the logical next steps in this era of virtual care. Telehealth is only growing in popularity and effectiveness. Now is the time for hospitals to augment their current telehealth practices with robust yet adaptable technology.”

The pandemic revealed two major findings about telehealth. 1) First, patients appreciate the convenience of home access to medical information and communication with providers. 2) Second, the technology for remote healthcare is insufficient for the needs of patients.

Providers and healthcare facilities are racing to upgrade systems to use telehealth more effectively in the near future. Remote telemetry for monitoring patients’ vital functions is a top technology priority. Industry analysts predict that the market for remote cardiac monitoring devices will grow from $6.48 billion to $11.49 billion annually by 2030.(2) Companies like InfoBionic are stepping up to provide the next generation of remote telemetry tools.

Telemetry refers to any system that allows medical staff to monitor patients without being present in the room. Hospital systems regularly use telemetry to monitor patients.

Patients in an ICU, for example, might be one of the most sophisticated stationary cardiac monitors that are remotely monitored 24/7 and incorporate that several life critical vital signs. In contrast, staff would use different telemetry systems designed to monitor patients with less acute needs, but the patient would still occupy a designated step-down or progressive care telemetry bed with continuous monitoring. These latter systems monitor fewer vital signs and are not intended for severely ill or the highest acuity patients. Further, they can be limited in their portability and often are confined to just these areas of the hospital, thereby making it difficult to transport patients to non-telemetry areas of the hospital like radiology or cardiology.

Hospitals have a limited number of beds that can accommodate the high- and mid-level telemetry that patients need. As a result, patients may remain in the ICU longer than necessary due to a lack of step-down beds. For many patients, monitoring is the only service they need from a hospital.

Advanced mobile telemetry would allow hospitals to accommodate patient needs in any bed.

InfoBionic’s MoMe™ ARC Platform* is being designed to be the first platform on the market to deliver that level of acuity, agility, and adaptability in virtual cardiac care. “We envisioned an entirely portable and adaptable system for cardiac monitoring,” says Long. “The monitors themselves are not tethered to a single area of a facility, allowing uninterrupted use even when a patient moves between departments.

The next generation MoMe* is being designed specifically for hospital telemetry to provide a step-down level of telemetry for any bed or location that would need an easy-to-deploy mobile telemetry monitor. Further, it builds on our core expertise to enable a seamless hospital-to-home patient transition where continuous monitoring from real-time to near real-time is essential for meeting the demands of virtual care monitoring.

For more information about InfoBionic, visit their website at https://infobionic.com/.

*This product has not been approved by the FDA for sale in the US.

About InfoBionic

InfoBionic’s digital technology has transformed the clinical efficiency and economics of cardiac remote patient monitoring. The company’s MoMe™ ARC platform has removed the roadblocks hindering remote diagnosis and clinical decision-making. The Massachusetts-based team of seasoned entrepreneurs have had successful careers in healthcare, IT, medical devices, and mobile technology and bring specific expertise in remote monitoring and cardiology. More recently, working side by side with the healthcare and medical technology communities, including its own competitors, InfoBionic has developed MoMe® Now, the first virtual telemetry system for high-acuity patients in remote, virtual, or hospital-at-home care environments. Visit https://InfoBionic.com/

References:

1. Morbidity and Mortality Weekly Report (MMWR). Trends in Use of Telehealth Among Health Centers During the COVID-19 Pandemic — United States, June 26–November 6, 2020. February 2021.

2. Acumen Research and Consulting. Cardiac Arrhythmia Monitoring Devices Market Analysis – Global Industry Size, Share, Trends and Forecast 2022 – 2030. June 2022.

Share article on social media or email: